Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Indy Hematology Review

A. Tefferi

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Top 5 Impactful MPN Abstracts From Summer Conferences

Insights from 2024 EHA Annual Meeting

P. Bose

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub